| Bioactivity | Ansuvimab (Ansuvimab-zyk) is a recombinant human monoclonal IgG1 antibody that exhibits antiviral activity against Zaire ebolavirus. Ansuvimab binds to the glycoprotein on Zaire ebolavirus to block its entry into host cells[1]. |
| Target | Zaire ebolavirus |
| Invitro | Ansuvimab 通过结合位于埃博拉病毒糖蛋白 (GP) 的 GP1 亚基受体结合位点的 LEIKKPDGS 表位来阻断 GP 与 Niemann-Pick C1 受体之间的结合[1]。Ansuvimab 对转染 GP 的靶细胞具有抗体依赖性细胞毒性 (ADCC)，在浓度为 0.03 μg/mL 时具有最大活性[3]。 |
| In Vivo | Ansuvimab 给药使所有猕猴在第 0 天暴露于致死剂量的埃博拉病毒后存活下来[1]。 |
| Name | Ansuvimab |
| CAS | 2375952-29-5 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Lee A, et, al. Ansuvimab: First Approval. Drugs. 2021 Apr;81(5):595-598. [2]. Corti D, et, al. Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody. Science. 2016 Mar 18;351(6279):1339-42. |